IQVIA Target of Unusually Large Options Trading (NYSE:IQV) (2024)

IQVIA Holdings Inc. (NYSE:IQV - Get Free Report) was the recipient of unusually large options trading activity on Monday. Stock traders acquired 2,157 put options on the stock. This is an increase of approximately 160% compared to the average volume of 830 put options.

Get IQVIA alerts:

IQVIA Trading Up 9.2 %

Shares of NYSE IQV traded up $20.66 during trading on Monday, hitting $245.23. 2,487,739 shares of the company traded hands, compared to its average volume of 1,076,352. IQVIA has a 1 year low of $167.42 and a 1 year high of $261.73. The firm has a market capitalization of $44.68 billion, a P/E ratio of 32.28, a P/E/G ratio of 2.05 and a beta of 1.49. The company has a quick ratio of 0.88, a current ratio of 0.88 and a debt-to-equity ratio of 2.02. The company has a 50-day moving average price of $219.54 and a 200-day moving average price of $228.91.

IQVIA (NYSE:IQV - Get Free Report) last issued its quarterly earnings data on Monday, July 22nd. The medical research company reported $2.64 EPS for the quarter, topping analysts' consensus estimates of $2.36 by $0.28. IQVIA had a return on equity of 29.17% and a net margin of 9.01%. The company had revenue of $3.81 billion for the quarter, compared to analysts' expectations of $3.79 billion. During the same quarter in the previous year, the firm posted $2.22 earnings per share. The firm's quarterly revenue was up 2.3% on a year-over-year basis. On average, equities analysts predict that IQVIA will post 10.11 EPS for the current year.

Ad Colonial MetalsCollapse of the PetrodollarThe death of the "petrodollar" seems imminent.And the implications could not be worse for Americans.Russia, China and India have decided to abandon the petrodollar.In answer to this issue, we have released a Special Report to the public.

Institutional Investors Weigh In On IQVIA

Several institutional investors and hedge funds have recently bought and sold shares of IQV. Lazard Asset Management LLC grew its position in IQVIA by 0.9% in the 1st quarter. Lazard Asset Management LLC now owns 3,263,944 shares of the medical research company's stock valued at $825,416,000 after buying an additional 30,014 shares in the last quarter. Canada Pension Plan Investment Board raised its holdings in IQVIA by 6.4% during the first quarter. Canada Pension Plan Investment Board now owns 3,191,835 shares of the medical research company's stock worth $807,183,000 after purchasing an additional 193,304 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. lifted its position in IQVIA by 3.8% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,510,685 shares of the medical research company's stock worth $634,927,000 after purchasing an additional 92,293 shares during the period. Capital Research Global Investors boosted its stake in IQVIA by 7.2% during the 1st quarter. Capital Research Global Investors now owns 2,138,802 shares of the medical research company's stock valued at $540,882,000 after purchasing an additional 143,533 shares in the last quarter. Finally, DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main raised its stake in shares of IQVIA by 339.6% in the 4th quarter. DZ BANK AG Deutsche Zentral Genossenschafts Bank Frankfurt am Main now owns 2,067,195 shares of the medical research company's stock worth $478,308,000 after buying an additional 1,597,003 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on IQV shares. StockNews.com raised shares of IQVIA from a "hold" rating to a "buy" rating in a research note on Monday, July 15th. Truist Financial decreased their price target on shares of IQVIA from $297.00 to $292.00 and set a "buy" rating for the company in a research note on Friday, May 3rd. Robert W. Baird dropped their price target on shares of IQVIA from $241.00 to $235.00 and set a "neutral" rating on the stock in a research note on Wednesday, July 10th. The Goldman Sachs Group assumed coverage on IQVIA in a report on Thursday, June 6th. They set a "buy" rating and a $270.00 price target on the stock. Finally, Evercore ISI reduced their price target on shares of IQVIA from $250.00 to $230.00 and set an "outperform" rating for the company in a research note on Tuesday, July 9th. Three equities research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $255.73.

Read Our Latest Stock Report on IQV

About IQVIA

(Get Free Report)

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Should you invest $1,000 in IQVIA right now?

Before you consider IQVIA, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.

While IQVIA currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report